Darovasertib data are promised for the last week of March.
ApexOnco Front Page
Recent articles
Just like other oral SERDs, filing is restricted to the ESR1-mutant population.
Komet-007 showed no differentiation syndrome, but the group didn’t disclose data on menin inhibitor-experienced patients.
Will a TIGIT refocus see the stars finally align for the partners?
The biotech surges on data with its new oncology lead, so could it have a new Padcev on its hands?
Merck adds an overall survival benefit while Bristol sinks further.
The Bristol drug's availability for adjuvant bladder cancer threw Keynote-123 out of kilter.
CG Oncology and Arrivent pull off US flotations, and both offer speculative investment cases.